EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Lisa Licitra,Robert I. Haddad,Caroline Even,Makoto Tahara,Mikhail Dvorkin,Tudor-Eliade Ciuleanu,Paul Clement,Ricard Mesia,Svetlana I. Kutukova,Lyubov Zholudeva,Amaury Daste,Javier Daroqui Caballero,Bhumsuk Keam,Ihor Vynnychenko,Cedrik Lafond,Jagdish Shetty,Nassim Morsli,Helen Mann,Jérôme Fayette,Robert L. Ferris

EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

2019

6012Background: EAGLE is a phase 3 study evaluating efficacy of D (anti-PD-L1 mAb) monotherapy and D+T (anti-CTLA-4 mAb) vs standard of care (SOC) in pts with R/M HNSCC who progressed following pla...

Keywords:

Pathology
Head and neck squamous-cell carcinoma
Durvalumab
Oncology
Tremelimumab
Eagle
Internal medicine
Medicine
standard of care
in patient
open label study
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations